Screener
ImmunityBio, Inc. IBRX Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s asset turnover?
- ImmunityBio, Inc. (IBRX) reported asset turnover of 0.3× in Q1 2026.
- How has ImmunityBio, Inc.'s asset turnover changed year-over-year?
- ImmunityBio, Inc.'s asset turnover increased by 234.9% year-over-year, from 0.1× to 0.3×.
- What is the long-term trend for ImmunityBio, Inc.'s asset turnover?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s asset turnover has grown at a 127.5% compound annual growth rate (CAGR), from 0× to 0.3×.
- What does asset turnover mean?
- Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.
Ask your AI about ImmunityBio, Inc.'s asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude